Microbiotica Secures £50 Million for Microbiome Therapies
Microbiotica, an innovative biotechnology company based in Cambridge, UK, specializes in the discovery and development of microbiome-based therapeutics and biomarkers. Recently, the company announced the successful closure of a £50 million (approximately $67 million) Series B financing round, a significant milestone that will aid in expanding its research and development initiatives. This funding round was co-led by prominent investors Flerie Invest and Tencent, with additional support from new investors like British Patient Capital. Existing stakeholders, including Cambridge Innovation Capital, IP Group, and Seventure Partners, also participated in this funding effort, emphasizing the high level of confidence in Microbiotica's clinical and commercial potential.
With the proceeds from this funding round, Microbiotica plans to advance its two lead oral Live Bacterial Therapeutics (LBTs), named MB097 and MB310, into Phase 1b clinical studies.
MB097 is particularly noteworthy as it is designed as a fully defined LBT that features a consortium of bacteria reflecting Microbiotica's proprietary clinical microbiome signature, which predicts how patients may respond to Immune Checkpoint Inhibitor therapy. On the other hand, MB310 holds promise for treating Ulcerative Colitis, having been linked to remission in prior fecal transplant clinical studies. As part of their expanded efforts, the company is also working to broaden its discovery pipeline of biomarkers and LBTs across various disease areas, thereby unlocking new avenues for therapeutic intervention.
Under the leadership of Co-Founder and CEO Mike Romanos, Microbiotica is committed to developing precision medicines grounded in robust clinical data. The company’s approach employs accurate clinical microbiome profiling through their proprietary platform, which correlates specific bacterial consortia with patient outcomes in clinical trials. This meticulous methodology has allowed Microbiotica to validate both MB097 and MB310 pre-clinically through comprehensive in vivo efficacy studies and ex vivo human cell data. Founded as a spin-out from the Wellcome Sanger Institute, Microbiotica has established fruitful partnerships with eminent organizations such as Cancer Research UK, Cambridge University Hospitals, the University of Adelaide, and Genentech, reinforcing its position at the forefront of microbiome therapeutics research.
They've invested in Microbiotica
Get to know these Biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 Tencent( ) | ||||
 Ip Group( ) | ||||
 Seventure Partners( ) | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK